WO2009005076A1 - アミド化合物 - Google Patents

アミド化合物 Download PDF

Info

Publication number
WO2009005076A1
WO2009005076A1 PCT/JP2008/061943 JP2008061943W WO2009005076A1 WO 2009005076 A1 WO2009005076 A1 WO 2009005076A1 JP 2008061943 W JP2008061943 W JP 2008061943W WO 2009005076 A1 WO2009005076 A1 WO 2009005076A1
Authority
WO
WIPO (PCT)
Prior art keywords
receptors
antagonistic activities
compounds
renal failure
diabetic nephropathy
Prior art date
Application number
PCT/JP2008/061943
Other languages
English (en)
French (fr)
Inventor
Eisuke Nozawa
Ryotaro Ibuka
Kazuhiro Ikegai
Keisuke Matsuura
Tatsuya Zenkoh
Ryushi Seo
Original Assignee
Astellas Pharma Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astellas Pharma Inc. filed Critical Astellas Pharma Inc.
Priority to JP2009521644A priority Critical patent/JP5408434B2/ja
Priority to US12/667,492 priority patent/US20110028463A1/en
Priority to EP08790794A priority patent/EP2172447A4/en
Priority to CA002692265A priority patent/CA2692265A1/en
Publication of WO2009005076A1 publication Critical patent/WO2009005076A1/ja

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/08—Indoles; Hydrogenated indoles with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to carbon atoms of the hetero ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C233/00—Carboxylic acid amides
    • C07C233/64—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings
    • C07C233/81—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C233/00—Carboxylic acid amides
    • C07C233/64—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings
    • C07C233/81—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups
    • C07C233/82—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom
    • C07C233/87—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom of a carbon skeleton containing six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
    • C07C235/42—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C243/00—Compounds containing chains of nitrogen atoms singly-bound to each other, e.g. hydrazines, triazanes
    • C07C243/24—Hydrazines having nitrogen atoms of hydrazine groups acylated by carboxylic acids
    • C07C243/38—Hydrazines having nitrogen atoms of hydrazine groups acylated by carboxylic acids with acylating carboxyl groups bound to carbon atoms of six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/79—Acids; Esters
    • C07D213/80—Acids; Esters in position 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/54—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
    • C07D231/56—Benzopyrazoles; Hydrogenated benzopyrazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/16—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms condensed with carbocyclic rings or ring systems
    • C07D249/18—Benzotriazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/52—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings condensed with carbocyclic rings or ring systems
    • C07D263/54—Benzoxazoles; Hydrogenated benzoxazoles
    • C07D263/56—Benzoxazoles; Hydrogenated benzoxazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D265/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
    • C07D265/28—1,4-Oxazines; Hydrogenated 1,4-oxazines
    • C07D265/34—1,4-Oxazines; Hydrogenated 1,4-oxazines condensed with carbocyclic rings
    • C07D265/36—1,4-Oxazines; Hydrogenated 1,4-oxazines condensed with carbocyclic rings condensed with one six-membered ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D271/00—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
    • C07D271/02—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms not condensed with other rings
    • C07D271/06—1,2,4-Oxadiazoles; Hydrogenated 1,2,4-oxadiazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/26—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D333/38—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2602/00—Systems containing two condensed rings
    • C07C2602/02—Systems containing two condensed rings the rings having only two atoms in common
    • C07C2602/04—One of the condensed rings being a six-membered aromatic ring
    • C07C2602/10—One of the condensed rings being a six-membered aromatic ring the other ring being six-membered, e.g. tetraline

Abstract

【課題】慢性腎不全治療剤又は糖尿病性腎症治療剤として有用な化合物を提供する。 【解決手段】発明者等は、EP4受容体拮抗作用を有する化合物について鋭意検討した結果、カルボキシル基又はその等価体を有する種々のアミド誘導体が良好なEP4受容体拮抗作用を示すことを知見し、本発明を完成させた。 　本発明化合物は、良好なEP4受容体拮抗作用を有することから、慢性腎不全又は糖尿病性腎症の予防剤及び/又は治療剤として有用である。
PCT/JP2008/061943 2007-07-03 2008-07-02 アミド化合物 WO2009005076A1 (ja)

Priority Applications (4)

Application Number Priority Date Filing Date Title
JP2009521644A JP5408434B2 (ja) 2007-07-03 2008-07-02 アミド化合物
US12/667,492 US20110028463A1 (en) 2007-07-03 2008-07-02 Amide compounds
EP08790794A EP2172447A4 (en) 2007-07-03 2008-07-02 amide
CA002692265A CA2692265A1 (en) 2007-07-03 2008-07-02 Amide compounds

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2007-174733 2007-07-03
JP2007174733 2007-07-03

Publications (1)

Publication Number Publication Date
WO2009005076A1 true WO2009005076A1 (ja) 2009-01-08

Family

ID=40226119

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2008/061943 WO2009005076A1 (ja) 2007-07-03 2008-07-02 アミド化合物

Country Status (5)

Country Link
US (1) US20110028463A1 (ja)
EP (2) EP2460787A1 (ja)
JP (1) JP5408434B2 (ja)
CA (1) CA2692265A1 (ja)
WO (1) WO2009005076A1 (ja)

Cited By (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009139373A1 (ja) 2008-05-14 2009-11-19 アステラス製薬株式会社 アミド化合物
EP2320906A1 (en) * 2008-08-14 2011-05-18 Beta Pharma Canada Inc. Heterocyclic amide derivatives as ep4 receptor antagonists
US8283465B2 (en) 2009-07-17 2012-10-09 Japan Tobacco Inc. Triazolopyridine compound, and action thereof as prolyl hydroxylase inhibitor or erythropoietin production-inducing agent
US20130184463A1 (en) * 2011-12-21 2013-07-18 Allergan, Inc. Compounds acting at multiple prostaglandin receptors giving a general anti-inflammatory response
JP2013536210A (ja) * 2010-08-27 2013-09-19 グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング Ｋｃｎｑ２／３調節因子としての置換された２−オキシ−キノリン−３−カルボキサミド
JP2013538825A (ja) * 2010-09-21 2013-10-17 エーザイ・アール・アンド・ディー・マネジメント株式会社 医薬組成物
WO2014200075A1 (ja) 2013-06-12 2014-12-18 科研製薬株式会社 ４－アルキニルイミダゾール誘導体およびそれを有効成分として含有する医薬
WO2015147020A1 (ja) * 2014-03-26 2015-10-01 アステラス製薬株式会社 アミド化合物
JP2016540007A (ja) * 2013-12-17 2016-12-22 イーライ リリー アンド カンパニー フェノキシエチル環状アミン誘導体およびｅｐ４受容体モジュレーターとしてのその活性
JP2017500309A (ja) * 2013-12-17 2017-01-05 イーライ リリー アンド カンパニー ジメチル安息香酸化合物
WO2017122754A1 (ja) 2016-01-12 2017-07-20 日本ケミファ株式会社 電位依存性ｔ型カルシウムチャネル阻害剤
JP2018527295A (ja) * 2015-07-23 2018-09-20 武田薬品工業株式会社 複素環化合物
WO2018210995A1 (en) 2017-05-18 2018-11-22 Idorsia Pharmaceuticals Ltd N-substituted indole derivatives
JP2020196731A (ja) * 2013-09-27 2020-12-10 アラーガン、インコーポレイテッドＡｌｌｅｒｇａｎ，Ｉｎｃｏｒｐｏｒａｔｅｄ 皮膚修復のための化合物及び方法
JP2021514939A (ja) * 2018-03-02 2021-06-17 シェンチェン イオノヴァ ライフ サイエンス カンパニー リミテッドＳｈｅｎｚｈｅｎ Ｉｏｎｏｖａ Ｌｉｆｅ Ｓｃｉｅｎｃｅ Ｃｏ．， Ｌｔｄ． ヘテロ二環式有機酸およびその塩類
JP2021521128A (ja) * 2018-04-17 2021-08-26 テンペスト セラピューティクス，インク． 二環式カルボキサミドおよびその使用方法
US11241431B2 (en) 2015-11-20 2022-02-08 Idorsia Pharmaceuticals Ltd N-substituted indole derivatives as PGE2 receptor modulators
JP2022522993A (ja) * 2019-01-22 2022-04-21 キーセラ・（スーチョウ）・ファーマシューティカルズ・カンパニー・リミテッド Ｐｇｅ２／ｅｐ４シグナル伝達を阻害する化合物、その製造方法及びその医薬における応用
US11325899B2 (en) 2017-05-18 2022-05-10 Idorsia Pharmaceuticals Ltd Benzofurane and benzothiophene derivatives as PGE2 receptor modulators
WO2022102731A1 (ja) 2020-11-13 2022-05-19 小野薬品工業株式会社 Ｅｐ４拮抗薬と免疫チェックポイント阻害物質との併用によるがん治療
US11446298B2 (en) 2017-05-18 2022-09-20 Idorsia Pharmaceuticals Ltd Pyrimidine derivatives
WO2023287241A1 (ko) * 2021-07-15 2023-01-19 주식회사 휴사이온 신규한 벤즈옥사졸아민 유도체 화합물 및 이를 포함하는 암의 예방 또는 치료용 약학 조성물
US11712438B2 (en) 2017-05-18 2023-08-01 Idorsia Pharmaceuticals Ltd Phenyl derivatives as PGE2 receptor modulators
US11839613B2 (en) 2017-05-18 2023-12-12 Idorsia Pharmaceuticals Ltd Pyrimidine derivatives as PGE2 receptor modulators

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA115576C2 (uk) 2012-12-06 2017-11-27 Байєр Фарма Акцієнгезелльшафт Похідні бензимідазолу як антагоністи ер4
EP2765128A1 (en) * 2013-02-07 2014-08-13 Almirall, S.A. Substituted benzamides with activity towards EP4 receptors
TW201607943A (zh) 2013-12-19 2016-03-01 拜耳製藥公司 作為ｅｐ４配體之新穎苯并咪唑衍生物
WO2018162562A1 (en) 2017-03-10 2018-09-13 Bayer Pharma Aktiengesellschaft Use of an ep4 antagonist for the treatment of inflammatory pain
US11066405B2 (en) 2017-04-18 2021-07-20 Tempest Therapeutics, Inc. Bicyclic compounds and their use in the treatment of cancer
CA3060554A1 (en) * 2017-04-18 2018-10-25 Tempest Therapeutics, Inc. Bicyclic compounds and their use in the treatment of cancer
WO2019038156A1 (en) 2017-08-22 2019-02-28 Bayer Pharma Aktiengesellschaft USE OF AN EP4 ANTAGONIST FOR THE TREATMENT OF ARTHRITIS
CN109836434B (zh) * 2017-11-27 2020-09-25 上海宇耀生物科技有限公司 噻吩并环类化合物及其合成方法和应用
WO2020251957A1 (en) * 2019-06-11 2020-12-17 Teon Therapeutics, Inc. Prostaglandin e2 receptor 4 antagonists and uses thereof
US20240109887A1 (en) * 2021-03-02 2024-04-04 Viva Star Biosciences (Suzhou) Co., Ltd. Novel substituted bicyclic aza-heterocycles as sos1 inhibitors
IL310592A (en) 2021-08-03 2024-04-01 Cytokinetics Inc The process of preparing apicamtan
WO2023160569A1 (en) * 2022-02-24 2023-08-31 Guangdong Newopp Biopharmaceuticals Co., Ltd. Carboxamide compounds as pge2 receptor antagonists

Citations (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0545790A (ja) * 1991-08-12 1993-02-26 Konica Corp 高感度・高鮮鋭性で、かつ処理ムラの少ないハロゲン化銀写真感光材料
JP2002501502A (ja) * 1997-04-25 2002-01-15 スミスクライン・ビーチャム・コーポレイション プロテアーゼ阻害物質
JP2002145840A (ja) * 2000-01-25 2002-05-22 Japan Tobacco Inc Ｎ−アリールヒドラジド化合物及びその医薬用途
WO2005021508A1 (en) 2003-09-03 2005-03-10 Pfizer Inc. Phenyl or pyridyl amide compounds as prostaglandin e2 antagonists
JP2005232149A (ja) * 2003-03-07 2005-09-02 Santen Pharmaceut Co Ltd ４−ピリジルアルキルチオ基を置換基として有する新規化合物
WO2005105733A1 (en) 2004-05-04 2005-11-10 Pfizer Japan Inc. Ortho substituted aryl or heteroaryl amide compounds
WO2005105732A1 (en) 2004-05-04 2005-11-10 Pfizer Japan Inc. Substituted methyl aryl or heteroaryl amide compounds
WO2007121578A1 (en) 2006-04-24 2007-11-01 Merck Frosst Canada Ltd. Indole amide derivatives as ep4 receptor antagonists
WO2007143825A1 (en) 2006-06-12 2007-12-21 Merck Frosst Canada Ltd. Indoline amide derivatives as ep4 receptor ligands
WO2008101716A2 (de) 2007-02-23 2008-08-28 Schenck Rotec Gmbh Verfahren und vorrichtung zur unwuchtmessung von rotoren mit unsymmetrischer massenverteilung

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0031315D0 (en) * 2000-12-21 2001-02-07 Glaxo Group Ltd Indole derivatives
WO2004078723A1 (ja) * 2003-03-07 2004-09-16 Santen Pharmaceutical Co. Ltd. ４－ピリジルアルキルチオ基を置換基として有する新規化合物
US8969394B2 (en) * 2006-08-11 2015-03-03 Merck Frosst Canada Ltd. Thiophenecarboxamide derivatives as EP4 receptor ligands
AU2007331471C1 (en) * 2006-12-15 2013-07-25 Glaxo Group Limited Benzamide derivatives as EP4 receptor agonists

Patent Citations (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0545790A (ja) * 1991-08-12 1993-02-26 Konica Corp 高感度・高鮮鋭性で、かつ処理ムラの少ないハロゲン化銀写真感光材料
JP2002501502A (ja) * 1997-04-25 2002-01-15 スミスクライン・ビーチャム・コーポレイション プロテアーゼ阻害物質
JP2002145840A (ja) * 2000-01-25 2002-05-22 Japan Tobacco Inc Ｎ−アリールヒドラジド化合物及びその医薬用途
JP2005232149A (ja) * 2003-03-07 2005-09-02 Santen Pharmaceut Co Ltd ４−ピリジルアルキルチオ基を置換基として有する新規化合物
WO2005021508A1 (en) 2003-09-03 2005-03-10 Pfizer Inc. Phenyl or pyridyl amide compounds as prostaglandin e2 antagonists
JP2007504210A (ja) * 2003-09-03 2007-03-01 ファイザー株式会社 プロスタグランジンｅ２拮抗薬としてのフェニルまたはピリジルアミド化合物
WO2005105733A1 (en) 2004-05-04 2005-11-10 Pfizer Japan Inc. Ortho substituted aryl or heteroaryl amide compounds
WO2005105732A1 (en) 2004-05-04 2005-11-10 Pfizer Japan Inc. Substituted methyl aryl or heteroaryl amide compounds
WO2007121578A1 (en) 2006-04-24 2007-11-01 Merck Frosst Canada Ltd. Indole amide derivatives as ep4 receptor antagonists
WO2007143825A1 (en) 2006-06-12 2007-12-21 Merck Frosst Canada Ltd. Indoline amide derivatives as ep4 receptor ligands
WO2008101716A2 (de) 2007-02-23 2008-08-28 Schenck Rotec Gmbh Verfahren und vorrichtung zur unwuchtmessung von rotoren mit unsymmetrischer massenverteilung

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
"Drug Design", vol. 7, 1990, HIROKAWA PUBLISHING COMPANY, article "Pharmaceutical Research and Development", pages: 163 - 198
PROG. MED., vol. 5, 1985, pages 2157 - 2161
See also references of EP2172447A4 *

Cited By (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8598355B2 (en) 2008-05-14 2013-12-03 Astellas Pharma Inc. Amide compound
EP2277858A4 (en) * 2008-05-14 2012-06-13 Astellas Pharma Inc AMIDE COMPOUND
WO2009139373A1 (ja) 2008-05-14 2009-11-19 アステラス製薬株式会社 アミド化合物
AU2009247262B2 (en) * 2008-05-14 2013-01-31 Astellas Pharma Inc. Amide compound
EP2565191A1 (en) * 2008-05-14 2013-03-06 Astellas Pharma Inc. 4-(Indol-7-ylcarbonylaminomethyl)cyclohexanecarboxylic acid derivatives as EP4 receptor antagonists useful for the treatment of chronic renal failure or diabetic nephropathy
JP5375824B2 (ja) * 2008-05-14 2013-12-25 アステラス製薬株式会社 アミド化合物
EP2320906A1 (en) * 2008-08-14 2011-05-18 Beta Pharma Canada Inc. Heterocyclic amide derivatives as ep4 receptor antagonists
EP2320906A4 (en) * 2008-08-14 2012-05-09 Beta Pharma Canada Inc HETEROCYCLIC AMIDE DERIVATIVES AS AN EP4 RECEPTOR ANTAGONISTS
US8404736B2 (en) 2008-08-14 2013-03-26 Beta Pharma Canada Inc. Heterocyclic amide derivatives as EP4 receptor antagonists
US8283465B2 (en) 2009-07-17 2012-10-09 Japan Tobacco Inc. Triazolopyridine compound, and action thereof as prolyl hydroxylase inhibitor or erythropoietin production-inducing agent
JP2013536210A (ja) * 2010-08-27 2013-09-19 グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング Ｋｃｎｑ２／３調節因子としての置換された２−オキシ−キノリン−３−カルボキサミド
JP2013538825A (ja) * 2010-09-21 2013-10-17 エーザイ・アール・アンド・ディー・マネジメント株式会社 医薬組成物
US20130184463A1 (en) * 2011-12-21 2013-07-18 Allergan, Inc. Compounds acting at multiple prostaglandin receptors giving a general anti-inflammatory response
US10988474B2 (en) 2011-12-21 2021-04-27 Allergan, Inc. Compounds acting at multiple prostaglandin receptors giving a general anti-inflammatory response
JP2015500882A (ja) * 2011-12-21 2015-01-08 アラーガン インコーポレイテッドＡｌｌｅｒｇａｎ，Ｉｎｃｏｒｐｏｒａｔｅｄ 一般的な抗炎症反応を与える複数のプロスタグランジン受容体において作用する化合物
US10392382B2 (en) 2011-12-21 2019-08-27 Allergan, Inc. Compounds acting at multiple prostaglandin receptors giving a general anti-inflammatory response
US9593081B2 (en) 2013-06-12 2017-03-14 Kaken Pharmaceutical Co., Ltd. 4-alkynyl imidazole derivative and medicine comprising same as active ingredient
WO2014200075A1 (ja) 2013-06-12 2014-12-18 科研製薬株式会社 ４－アルキニルイミダゾール誘導体およびそれを有効成分として含有する医薬
US9855257B2 (en) 2013-06-12 2018-01-02 Kaken Pharmaceutical Co., Ltd. 4-alkynyl imidazole derivative and medicine comprising same as active ingredient
KR20160018745A (ko) 2013-06-12 2016-02-17 가껭세이야꾸가부시기가이샤 4-알키닐이미다졸 유도체 및 그것을 유효 성분으로서 함유하는 의약
JP2020196731A (ja) * 2013-09-27 2020-12-10 アラーガン、インコーポレイテッドＡｌｌｅｒｇａｎ，Ｉｎｃｏｒｐｏｒａｔｅｄ 皮膚修復のための化合物及び方法
JP2016540007A (ja) * 2013-12-17 2016-12-22 イーライ リリー アンド カンパニー フェノキシエチル環状アミン誘導体およびｅｐ４受容体モジュレーターとしてのその活性
JP2017500309A (ja) * 2013-12-17 2017-01-05 イーライ リリー アンド カンパニー ジメチル安息香酸化合物
KR20160138098A (ko) 2014-03-26 2016-12-02 아스테라스 세이야쿠 가부시키가이샤 아미드 화합물
US10106523B2 (en) 2014-03-26 2018-10-23 Astellas Pharma Inc. Amide compound
WO2015147020A1 (ja) * 2014-03-26 2015-10-01 アステラス製薬株式会社 アミド化合物
JPWO2015147020A1 (ja) * 2014-03-26 2017-04-13 アステラス製薬株式会社 アミド化合物
JP2018527295A (ja) * 2015-07-23 2018-09-20 武田薬品工業株式会社 複素環化合物
US11241431B2 (en) 2015-11-20 2022-02-08 Idorsia Pharmaceuticals Ltd N-substituted indole derivatives as PGE2 receptor modulators
WO2017122754A1 (ja) 2016-01-12 2017-07-20 日本ケミファ株式会社 電位依存性ｔ型カルシウムチャネル阻害剤
WO2018210995A1 (en) 2017-05-18 2018-11-22 Idorsia Pharmaceuticals Ltd N-substituted indole derivatives
US11446298B2 (en) 2017-05-18 2022-09-20 Idorsia Pharmaceuticals Ltd Pyrimidine derivatives
US11839613B2 (en) 2017-05-18 2023-12-12 Idorsia Pharmaceuticals Ltd Pyrimidine derivatives as PGE2 receptor modulators
US11712438B2 (en) 2017-05-18 2023-08-01 Idorsia Pharmaceuticals Ltd Phenyl derivatives as PGE2 receptor modulators
US11325899B2 (en) 2017-05-18 2022-05-10 Idorsia Pharmaceuticals Ltd Benzofurane and benzothiophene derivatives as PGE2 receptor modulators
JP2021514939A (ja) * 2018-03-02 2021-06-17 シェンチェン イオノヴァ ライフ サイエンス カンパニー リミテッドＳｈｅｎｚｈｅｎ Ｉｏｎｏｖａ Ｌｉｆｅ Ｓｃｉｅｎｃｅ Ｃｏ．， Ｌｔｄ． ヘテロ二環式有機酸およびその塩類
JP7361713B2 (ja) 2018-04-17 2023-10-16 テンペスト セラピューティクス，インク． 二環式カルボキサミドおよびその使用方法
US11795156B2 (en) 2018-04-17 2023-10-24 Tempest Therapeutics, Inc. Bicyclic carboxamides and methods of use thereof
JP2021521128A (ja) * 2018-04-17 2021-08-26 テンペスト セラピューティクス，インク． 二環式カルボキサミドおよびその使用方法
JP2022522993A (ja) * 2019-01-22 2022-04-21 キーセラ・（スーチョウ）・ファーマシューティカルズ・カンパニー・リミテッド Ｐｇｅ２／ｅｐ４シグナル伝達を阻害する化合物、その製造方法及びその医薬における応用
WO2022102731A1 (ja) 2020-11-13 2022-05-19 小野薬品工業株式会社 Ｅｐ４拮抗薬と免疫チェックポイント阻害物質との併用によるがん治療
WO2023287241A1 (ko) * 2021-07-15 2023-01-19 주식회사 휴사이온 신규한 벤즈옥사졸아민 유도체 화합물 및 이를 포함하는 암의 예방 또는 치료용 약학 조성물

Also Published As

Publication number Publication date
EP2172447A4 (en) 2011-08-24
EP2172447A1 (en) 2010-04-07
EP2460787A1 (en) 2012-06-06
US20110028463A1 (en) 2011-02-03
JPWO2009005076A1 (ja) 2010-08-26
JP5408434B2 (ja) 2014-02-05
CA2692265A1 (en) 2009-01-08

Similar Documents

Publication Publication Date Title
WO2009005076A1 (ja) アミド化合物
WO2007086001A3 (en) Novel pyridine derivatives
WO2008034736A3 (en) Oxindole derivatives as anticancer agents
DK2137184T3 (da) Imidazo[1,2-a]pyridinforbindelser som receptor-tyrosinkinaseinhibitorer
WO2009042114A3 (en) Phenazine derivatives and uses thereof
EP2631235A3 (en) Pest control agent
DK2201012T3 (da) Pyrrolo[2,3-d]pyrimidinderivater som proteinkinase b-hæmmere
DK2057154T3 (da) PYRIDO-(2,3-B)pyrazinderivater, der er anvendelige som herbicidale forbindelser
GT200900014A (es) Derivados de i-(-d-glucopiranosil)-3-(4-ciclopropilfenilmetil)-4-halogeno indoly uso de los mismos como inhibidores de los transportadores de glucosa dependientes de sodio.
DK2197844T3 (da) Spiroheterocykliske pyrrolidindionderivater, der er anvendelige som pesticider
DK1904494T3 (da) Imidazo[1,2-A]pyridin-forbindelser som VEGF-R2-inhibitorer
HK1167397A1 (zh) 作為抗癌症劑的 -取代的喹唑酮衍生物
AU2006253863A8 (en) Novel Heterocyclic compounds as positive allosteric modulators of metabotropic glutamate receptors
DK2350075T3 (da) Substituerede imidazo[1,2b]pyridazinforbindelser som trk-kinase-inhibitorer
WO2007148185A3 (en) Substituted 3 -amino- pyrrolidino-4 -lactams as dpp inhibitors
WO2007098474A8 (en) Phenyl-cycloalkyl and phenyl-heterocyclic derivatives as s1p receptor agonists
DK2029549T3 (da) Phenyl-pyrazol-derivater som ikke-steroide glucocoricoid-receptorligander
WO2007149829A3 (en) Therapeutic compounds
HK1102597A1 (en) 1,1'-(1,2-ethynediyl)bis-benzene derivatives as ptp 1-b inhibitors
WO2007142905A3 (en) 1-sulfonylindazolylamine and -amide derivatives as 5-hydroxytryptamine-6 ligands
AU2009279137A8 (en) Pyrazolo [5,1-b] oxazole derivatives as CRF1 antagonists
WO2008008700A3 (en) Substituted cyclopentane derivatives as therapeutic agents
WO2006134499A3 (en) 2-(1h-indolylsulfanyl)-aryl amine derivatives
WO2008092615A3 (en) Herbicidal composition comprising pinoxaden
WO2008068299A3 (en) Hydrobromide salt of an anti-hiv compound

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08790794

Country of ref document: EP

Kind code of ref document: A1

ENP Entry into the national phase

Ref document number: 2009521644

Country of ref document: JP

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 2692265

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2008790794

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 12667492

Country of ref document: US

NENP Non-entry into the national phase

Ref country code: DE